Influence of rheumatoid factor on serum drug levels of tumour necrosis factor inhibitors with different structures in rheumatoid arthritis
Authors' conclusion
In this real word data evaluation, CZP serum levels were independent of RF levels in patients however patients with high baseline RF levels who obtained IFX or ADL had lower serum drug levels at 6 months than baseline RF-negative patients.
Study context
- Population
- Real-world patients with RA treated with IFX, ADL or certolizumab pegol (CZP), stratified by baseline RF and ACPA levels
- Participants
- 170 patients
- Exposure
- Effect of baseline RF on serum drug levels of IFX, ADL and CZP
- IFXn = 90
- ADLn = 48
- CZPn = 32
- Outcome
- Serum drug levels by baseline RF level
- Follow-up
- 6 months (T6)
Methodological detailsreal-world
- Real-world
Main finding
As reported in the abstract
Serum drug levels by baseline RF · T6
- CZP serum levels did not differ across RF groups at T6
- High baseline RF linked to lower serum drug levels vs RF negative status with IFX and ADL
Observational data: associations, not effects.
Further findings
Drop-out by secondary non-response in patients with high baseline RF — IFX vs CZP · IFX vs ADL vs CZP
P = 0.002
Events
| Outcome | IFX | ADL | CZP |
|---|---|---|---|
| ADAb · 6 months | 26 | 3 | 1 |
Disease activity (DAS28) at baseline across RF quartiles
- No differences across RF quartiles in patients treated with IFX or ADL
Original publication
Influence of rheumatoid factor on serum drug levels of tumour necrosis factor inhibitors with different structures in rheumatoid arthritis. Clin Exp Rheumatol. Published 30 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →